Skip to main content
SpringerLink
Log in
Book cover

Clinical Ophthalmic Oncology pp 201–217Cite as

Uveal Melanoma: Brachytherapy

  • Chapter
  • First Online:

Abstract

In 1930, Sir Foster Moore first used brachytherapy for uveal melanoma by inserting radon-222 seeds directly into the tumor (Moore, Br J Ophthalmol 14:145–152, 1930). This technique was later modified by Stallard and eventually further refined using radioactive plaques containing cobalt-60 anchored to the episcleral surface (Stallard, Br J Ophthalmol 32(9):618–639, 1948; Stallard, Br J Ophthalmol 50(3):147–155, 1966). In the United States, this radionuclide was gradually replaced by plaques loaded with iodine-125 seeds, as this provided less radiation to surrounding tissues (Sealy et al., Br J Radiol 49(582):551–554, 1976; Packer and Rotman, Ophthalmology 87(6):582–590, 1980). In Europe, the pioneering work of Lommatzsch in the 1970s led to the introduction of ruthenium-106 as a radioactive source for episcleral brachytherapy of uveal melanoma (Lommatzsch, Surv Ophthalmol 19(2):85–100, 1974). Although observational data suggested that there was no survival difference compared to patients enucleated for uveal melanoma, it had not been confirmed in a randomized control trial until the Collaborative Ocular Melanoma Study (COMS) was launched in the mid-1980s. This included patients with medium-sized uveal melanoma, who had equal 5-year and 10-year survival rates in the enucleation and iodine brachytherapy groups (Collaborative Ocular Melanoma Study Group, Arch Ophthalmol 119:969–982, 2001; Collaborative Ocular Melanoma Study Group, Arch Ophthalmol 124:1684–1693, 2006). Ever since, brachytherapy has been a mainstay treatment within this size group. Smaller tumors are generally observed for growth or in selected cases treated with transpupillary thermotherapy, while patients with larger tumors still undergo enucleation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Moore RF. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol. 1930;14(4):145–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Stallard HB. Radiotherapy of malignant intra-ocular neoplasms. Br J Ophthalmol. 1948;32(9):618–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol. 1966;50(3):147–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sealy R, le Roux PL, Rapley F, et al. The treatment of ophthalmic tumours with low-energy sources. Br J Radiol. 1976;49(582):551–4.

    Article  CAS  PubMed  Google Scholar 

  5. Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology. 1980;87(6):582–90.

    Article  CAS  PubMed  Google Scholar 

  6. Lommatzsch P. Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators. Surv Ophthalmol. 1974;19(2):85–100.

    CAS  PubMed  Google Scholar 

  7. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III. Initial mortality findings. COMS report No. 18. Arch Ophthalmol. 2001;119:969–82.

    Article  Google Scholar 

  8. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. V. Twelve-year mortality rates and prognostic factors. COMS report No. 28. Arch Ophthalmol. 2006;124:1684–93.

    Article  Google Scholar 

  9. Stannard C, Sauerwein W, Maree G, et al. Radiotherapy for ocular tumours. Eye (Lond). 2013;27(2):119–27.

    Article  CAS  Google Scholar 

  10. Bergman L, Nilsson B, Lundell G, et al. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112(5):834–40.

    Article  PubMed  Google Scholar 

  11. Damato B, Patel I, Campbell IR, et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63(2):385–91.

    Article  PubMed  Google Scholar 

  12. Finger PT, Chin KJ, Duvall G, et al. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790–6. 796.e1.

    Article  PubMed  Google Scholar 

  13. Karvat A, Duzenli C, Ma R, et al. The treatment of choroidal melanoma with 198 Au plaque brachytherapy. Radiother Oncol. 2001;59(2):153–6.

    Article  CAS  PubMed  Google Scholar 

  14. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219–28.

    Article  CAS  PubMed  Google Scholar 

  15. Missotten L, Dirven W, Van der Schueren A, et al. Results of treatment of choroidal malignant melanoma with high-dose-rate strontium-90 brachytherapy. A retrospective study of 46 patients treated between 1983 and 1995. Graefes Arch ClinExpOphthalmol. 1998;236(3):164–73.

    Article  CAS  Google Scholar 

  16. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.

    Google Scholar 

  17. Echegaray JJ, Bechrakis NE, Singh N, et al. Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose. Ocul Oncol Pathol. 2017;3(3):193–8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Fili M, Lundell G, Lundell M, et al. High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome. Br J Ophthalmol. 2014;98(10):1349–54.

    Article  CAS  PubMed  Google Scholar 

  19. Shah NV, Houston SK, Murray TG, et al. Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review. Clin Ophthalmol. 2012;6:447–52.

    PubMed  PubMed Central  Google Scholar 

  20. Gunduz K, Shields CL, Shields JA, et al. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am J Ophthalmol. 2000;130(1):97–102.

    Article  CAS  PubMed  Google Scholar 

  21. Muen WJ, Damato BE. Uveal malignant melanoma with extrascleral extension, treated with plaque radiotherapy. Eye (Lond). 2007;21(2):307–8.

    Article  CAS  Google Scholar 

  22. Williams DF, Mieler WF, Jaffe GJ, et al. Magnetic resonance imaging of juxtapapillary plaques in cadaver eyes. Br J Ophthalmol. 1990;74(1):43–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Damato B, Patel I, Campbell IR, et al. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys. 2005;63(2):392–400.

    Article  PubMed  Google Scholar 

  24. Tabandeh H, Chaudhry NA, Murray TG, et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2):199–204.

    Article  CAS  PubMed  Google Scholar 

  25. Russo A, Laguardia M, Damato B. Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma. Graefes Arch Clin Exp Ophthalmol. 2012;250:1533–40.

    Article  PubMed  Google Scholar 

  26. Augsburger JJ, Gamel JW, Shields JA, et al. Post-irradiation regression of choroidal melanomas as a risk factor for death from metastatic disease. Ophthalmology. 1987;94(9):1173–7.

    Article  CAS  PubMed  Google Scholar 

  27. Rashid M, Heikkonen J, Singh AD, et al. Clinical predictors of regression of choroidal melanomas after brachytherapy: a growth curve model. Ophthalmology. 2018;125(5):747–54.

    Article  PubMed  Google Scholar 

  28. Damato B. Predicting choroidal melanoma regression after brachytherapy. Ophthalmology. 2018;125(5):755–6.

    Article  PubMed  Google Scholar 

  29. Laube T, Fluhs D, Kessler C, et al. Determination of surgeon’s absorbed dose in iodine 125 and ruthenium 106 ophthalmic plaque surgery. Ophthalmology. 2000;107(2):366–8; discussion 368–9.

    Article  CAS  PubMed  Google Scholar 

  30. Shields CL, Naseripour M, Shields JA, et al. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol. 2003;135(5):648–56.

    Article  PubMed  Google Scholar 

  31. Fluhs D, Anastassiou G, Wening J, et al. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators. Med Phys. 2004;31(6):1481–8.

    Article  CAS  PubMed  Google Scholar 

  32. Astrahan MA, Szechter A, Finger PT. Design and dosimetric considerations of a modified COMS plaque: the reusable “seed-guide” insert. Med Phys. 2005;32(8):2706–16.

    Article  PubMed  Google Scholar 

  33. Seregard S, Landau I. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma. Acta Ophthalmol Scand. 2001;79(1):19–22.

    Article  CAS  PubMed  Google Scholar 

  34. Bartlema YM, Oosterhuis JA, Journee-De Korver JG, et al. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years’ experience. Br J Ophthalmol. 2003;87(11):1370–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol. 1996;80(2):102–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Damato BE, Groenewald C, Foulds WS. Surgical resection of choroidal melanoma. In: Ryan SJ, editor. Retina, vol. 3. 5th ed. London: Elsevier; 2013. p. 2298–306.

    Chapter  Google Scholar 

  37. Puusaari I, Heikkonen J, Kivela T. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Invest Ophthalmol Vis Sci. 2004;45(10):3425–34.

    Article  PubMed  Google Scholar 

  38. Collaborative Ocular Melanoma Study. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS report No. 27. Ophthalmology. 2007;114(7):1363–71.

    Article  Google Scholar 

  39. Wen JC, Oliver SC, McCannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye (Lond). 2009;23(6):1254–68.

    Article  CAS  Google Scholar 

  40. Robertson DM, Fuller DG, Anderson RE. A technique for accurate placement of episcleral iodine-125 plaques. Am J Ophthalmol. 1987;103(1):63–5.

    Article  CAS  PubMed  Google Scholar 

  41. Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84(9):1068–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Summanen P, Immonen I, Kivela T, et al. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma. Br J Ophthalmol. 1996;80(8):732–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Krema H, Xu W, Payne D, et al. Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma. Can J Ophthalmol. 2011;46(2):158–63.

    Article  PubMed  Google Scholar 

  44. Mourtada F, Koch N, Newhauser W. 106Ru/106Rh plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study. Radiat Prot Dosimetry. 2005;116(1–4 Pt 2):454–60.

    Article  CAS  PubMed  Google Scholar 

  45. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2005;89(6):730–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Damato B. Vasculopathy after treatment of choroidal melanoma. In: Joussen A, Gardner TW, Kirchhof B, Ryan SJ, editors. Retinal vascular disease. Berlin: Springer; 2007. p. 582–91.

    Chapter  Google Scholar 

  47. Shields CL, Demirci H, Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina. 2005;25(7):868–74.

    Article  PubMed  Google Scholar 

  48. Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. Ophthalmology. 2009;116(7):1383–90.

    Article  PubMed  Google Scholar 

  49. Shah SU, Shields CL, Bianciotto CG, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121(1):269–75.

    Article  PubMed  Google Scholar 

  50. Khan N, Khan MK, Bena J, et al. Plaque brachytherapy for uveal melanoma: a vision prognostication model. Int J Radiat Oncol Biol Phys. 2012;84(3):e285–90.

    Article  PubMed  Google Scholar 

  51. Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond). 2013;27(2):163–71.

    Article  CAS  Google Scholar 

  52. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. 2008;70(4):974–7.

    Article  CAS  PubMed  Google Scholar 

  53. Detorakis ET, Engstrom RE Jr, Wallace R, et al. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma. Ophthalmology. 2005;112(3):505–10.

    Article  PubMed  Google Scholar 

  54. Kaliki S, Shields CL, Rojanaporn D, et al. Scleral necrosis after plaque radiotherapy of uveal melanoma: a case–control study. Ophthalmology. 2013;120:1004–11.

    Article  PubMed  Google Scholar 

  55. Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–66.

    Article  CAS  PubMed  Google Scholar 

  56. Puusaari I, Heikkonen J, Summanen P, et al. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110(11):2223–34.

    Article  PubMed  Google Scholar 

  57. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109(12):2197–206.

    Article  PubMed  Google Scholar 

  58. Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for juxtapapillarychoroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology. 2011;118(2):402–7.

    Article  PubMed  Google Scholar 

  59. Papageorgiou KI, Cohen VM, Bunce C, et al. Predicting local control of choroidal melanomas following 106Ru plaque brachytherapy. Br J Ophthalmol. 2011;95(2):166–70.

    Article  CAS  PubMed  Google Scholar 

  60. Filì M, Trocmé E, Bergman L, et al. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. Br J Ophthalmol. 2019; https://doi.org/10.1136/bjophthalmol-2018-313419. [Epub ahead of print]

  61. Seregard S, Lundell G, Lax I, et al. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma. Acta Ophthalmol Scand. 1997;75(2):148–54.

    Article  CAS  PubMed  Google Scholar 

  62. Avery RB, Diener-West M, Reynolds SM, et al. Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study. Arch Ophthalmol. 2008;126(2):207–12.

    Article  PubMed  Google Scholar 

  63. Toivonen P, Kivela T. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology. 2006;113(5):865–73.

    Article  PubMed  Google Scholar 

  64. Seregard S, aft Trampe E, Lax I, et al. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand. 1997;75(1):11–6.

    Article  CAS  PubMed  Google Scholar 

  65. Arnljots TS, Al-Sharbaty Z, Lardner E, et al. Tumour thickness, diameter, area or volume? The prognostic significance of conventional versus digital image analysis-based size estimation methods in uveal melanoma. Acta Ophthalmol Scand. 2018;96(5):510–8.

    Article  Google Scholar 

  66. Brandberg Y, Kock E, Oskar K, et al. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. Eye (Lond). 2000;14(Pt 6):839–46.

    Article  CAS  Google Scholar 

  67. Brandberg Y, Damato B, Kivela T, et al. The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (Phase I-III). Eye (Lond). 2004;18(3):283–9.

    Article  CAS  Google Scholar 

  68. Damato B, Hope-Stone L, Cooper B, et al. Patient-reported outcomes and quality of life after treatment of choroidal melanoma. A comparison of enucleation versus radiotherapy in 1596 patients. Am J Ophthalmol. 2018;193(1):230–51.

    Article  PubMed  Google Scholar 

  69. Shields CL, Naseripour M, Cater J, et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology. 2002;109(10):1838–49.

    Article  PubMed  Google Scholar 

  70. Stålhammar G, See TRO, Filì M, et al. No gender differences in long-term survival after brachytherapy of 1,541 patients with uveal melanoma. Ocul Oncol Pathol. 2019; https://doi.org/10.1159/000497186. [Epub ahead of print].

Download references

Author information

Authors and Affiliations

  1. Ophthalmic Pathology and Oncology Service and Department of Clinical Neuroscience, St. Erik Eye Hospital and Karolinska Institutet, Stockholm, Sweden

    Gustav Stålhammar & Stefan Seregard

  2. Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

    Bertil E. Damato

Authors
  1. Gustav Stålhammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Seregard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bertil E. Damato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gustav Stålhammar .

Editor information

Editors and Affiliations

  1. University of Oxford, Oxford, UK

    Bertil E. Damato

  2. Cole Eye Institute Cleveland Clinic, Cleveland, OH, USA

    Arun D. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Stålhammar, G., Seregard, S., Damato, B.E. (2019). Uveal Melanoma: Brachytherapy. In: Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-17879-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-17879-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-17878-9

  • Online ISBN: 978-3-030-17879-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation